科济生物医药（上海）有限公司

Chinese cell therapy company founded in 2014 by Li Zonghai and headquartered in Shanghai, with its holding company listed on the Hong Kong Stock Exchange under code 2171 since June 2021. Develops chimeric antigen receptor T cell therapies for haematological cancers and solid tumours, with the BCMA directed zevorcabtagene autoleucel approved in China for relapsed or refractory multiple myeloma and the Claudin18.2 directed satricabtagene autoleucel as the first CAR-T therapy for solid tumours, supported by its own manufacturing facilities in Shanghai and in Goleta, California.